title: Absence of relationship between plasma Lp(a), Lp-AI, anti-oxidized LDL autoantibodies, LDL immune complexes concentrations and restenosis after percutaneous transluminal coronary angioplasty.
abstract: To determine the relation between the concentration of Lp(a), LpAI, immunological markers of LDL oxidation (antioxidized-LDL autoantibodies (LDL-AB), LDL immune complexes (LDL-IC)) and restenosis after percutaneous transluminal coronary angioplasty (PTCA) in a Caucasian population (France), we studied 77 consecutive patients who successfully underwent PTCA. All were evaluated by follow-up angiography at an average of 6 months after PTCA and were divided into two groups: existence of restenosis (32 patients, group (G+)) and absence of restenosis (45 patients, negative group (G-)). The prevalence of diabetes mellitus was higher in the restenosis positive group than in the negative group (28% versus 2% respectively, P=0.001). Before and after adjustment in diabetes mellitus frequency there was no difference in the usual lipid parameters (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, phospholipids, apolipoprotein AI, apolipoprotein B) between the two groups of patients nor in the other parameters (Before adjustment: Lp(a): 0.306+/-0.352 g/l (G+) vs. 0.263+/-0.270 g/l (G-); LpAI: 0.414+/-0.126 g/l (G+) vs. 0.390+/-0.092 g/l (G-); LDL-AB: arbitrary unit (AU) 3.75+/-1.91 (G+) vs. 3.67+/-1.24 (G-); LDL-IC: (AU) 0.93+/-0.82 (G+) vs. 0.86+/-0.44 (G-)). Spearman correlation coefficients did not report any correlation between late loss, loss index, gain and the above mentioned plasma parameters. In conclusion, usual tested plasma lipids, Lp(a), LpAI and in vivo markers of LDL oxidation (LDL-AB and LDL-IC) are not risk factors for restenosis after PTCA in this French population.
authors.affiliation: Département d'Athérosclérose, INSERM U 325, Institut Pasteur et Université de Lille II, 1 rue du Professeur Calmette, BP 245, 59019 cedex, Lille, France.
authors.forename: A
authors.initials: A
authors.lastname: Boullier
authors.forename: E
authors.initials: E
authors.lastname: Walters-Laporte
authors.forename: M
authors.initials: M
authors.lastname: Hamon
authors.forename: A
authors.initials: A
authors.lastname: Tailleux
authors.forename: C
authors.initials: C
authors.lastname: Amant
authors.forename: P
authors.initials: P
authors.lastname: Amouyel
authors.forename: J
authors.initials: J
authors.lastname: Fruchart
authors.forename: M
authors.initials: M
authors.lastname: Bertrand
authors.forename: P
authors.initials: P
authors.lastname: Duriez
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000936:Antigen-Antibody Complex / Q000097:blood*; D001323:Autoantibodies / Q000097:blood*; D017023:Coronary Angiography; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000097:blood*; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood*; D008077:Lipoproteins, LDL / Q000276:immunology*; D008297:Male; D008315:Malondialdehyde / Q000276:immunology; D008875:Middle Aged; D010084:Oxidation-Reduction
chemical_list: D000936:Antigen-Antibody Complex; D001323:Autoantibodies; D017270:Lipoprotein(a); D008077:Lipoproteins, LDL; D008315:Malondialdehyde